OneSource Specialty Pharma (ONESOURCE) — Annual Report

📢 Key Event
OneSource Specialty Pharma Ltd filed its Integrated Annual Report 2025-26 on BSE, outlining FY26 performance, strategic expansion, and ESG commitments.

🔄 What Changed

Revenue declined 2% to ₹14,216 million (FY26), EBITDA margin stable at 21%, adjusted PAT of ₹739 million; credit rating upgraded with borrowing costs below 9%; $80 million capex committed; ₹70 crore Karnataka incentives secured; no material regulatory penalties.

🔮 What's Next
Target $400M revenue and 40% EBITDA margin by FY28; FY27 transition to commercial scale; continued expansion of CDMO capabilities; focus on GLP-1 therapies and DDC pipeline; sustained ESG integration and sustainability leadership.

💡 Investor Takeaway
FY26 showed resilient margins despite revenue pressure, with strategic investments advancing commercial scale readiness and long-term growth targets.

OneSource Specialty Pharma Ltd (ONESOURCE) filed its Integrated Annual Report 2025-26 on BSE (August 31, 2026), detailing FY26 performance, strategic direction, and ESG commitments. The report highlights a 2% revenue decline to ₹14,216 million due to delayed semaglutide approvals in Canada, while maintaining EBITDA of ₹3,042 million (21% margin) and adjusted PAT of [amount context mismatch] million. The company advanced its US$100 million expansion program, with $80 million committed to infrastructure and capacity scaling, and secured ₹70 crore in Karnataka state incentives. Key developments include full integration of DDC, biologics, injectables, and softgels platforms, a credit rating upgrade reducing borrowing costs below 9%, and proactive risk management addressing supply chain and regulatory challenges. ESG progress includes UNGC membership, improved sustainability ratings, and CDP Climate/Water ratings retention. The CFO emphasizes FY27 as the transition to commercial scale, targeting $400M revenue and 40% EBITDA margin by FY28, supported by pipeline momentum and expanded customer engagements.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ONESOURCE ✨ Ask AI About This

About OneSource Specialty Pharma Ltd (ONESOURCE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹17,366.55 Cr ROE: -0.8% ROCE: 0.9%

View full ONESOURCE stock details →

📡 Get AI alerts when ONESOURCE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ONESOURCE — Free

💡 Ask AI about this filing

"What is the timeline for achieving the $400M revenue target by FY28?" "How will the company address the delayed semaglutide approvals in Canada?" "What specific risks are associated with the $80 million committed capex program?"

Ask AI Free →

📊 More ONESOURCE filings

See all ONESOURCE filings →

🔥 Also filed on 31 August 2026

ARKADE Arkade Developers Ltd Annual Report DCBBANK DCB Bank Ltd Corporate Action HIKAL Hikal Ltd Annual Report 514470 Winsome Textile Industries Ltd Annual Report 523896 AVI Products India Ltd Annual Report JKIL J Kumar Infraprojects Ltd Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ONESOURCE files new disclosures

Track ONESOURCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ONESOURCE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd